Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
Top Cited Papers
- 1 October 2008
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 9 (10) , 962-972
- https://doi.org/10.1016/s1470-2045(08)70206-7
Abstract
No abstract availableKeywords
This publication has 85 references indexed in Scilit:
- Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: A chromogenic in situ hybridization study of 182 patientsLung Cancer, 2008
- PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patientsBritish Journal of Cancer, 2007
- EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitorsCritical Reviews in Oncology/Hematology, 2007
- Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapyBritish Journal of Cancer, 2007
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Cancer genes and the pathways they controlNature Medicine, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- RAF/RAS oncogenes and mismatch-repair statusNature, 2002
- EGFR and cancer prognosisPublished by Elsevier ,2001
- Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ studyBritish Journal of Cancer, 2001